• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

    45.35 +0.26 (+0.58%)
    Streaming Delayed Price Updated: 1:17 PM EDT, Jun 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 140,652
    Open 45.06
    Bid (Size) 45.31 (100)
    Ask (Size) 45.35 (100)
    Prev. Close 45.09
    Today's Range 44.41 - 45.88
    52wk Range 30.83 - 59.68
    Shares Outstanding 53,145,884
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    1 Cash-Heavy Stock on Our Watchlist and 2 Facing Challenges
    Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
    Via StockStory
    News headline image
    Supernus Pharmaceuticals to Participate in June Investor Conferences
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -8.3%
    -8.3%
    1 Month
    -8.1%
    -8.1%
    3 Month
    -14.8%
    -14.8%
    6 Month
    -1.8%
    -1.8%
    1 Year
    +36.3%
    +36.3%

    More News

    Read More
    News headline image
    3 Stocks Under $50 with Open Questions
    Via StockStory
    News headline image
    3 Small-Cap Stocks That Concern Us
    Via StockStory
    Topics Artificial Intelligence
    Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q1 Estimates as Growth Products Drive 39% Revenue Surge ↗
    Via Chartmill
    Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Posts Strong Q4 Beat as CNS Portfolio Accelerates Growth ↗
    Via Chartmill
    News headline image
    3 Growth Stocks We Approach with Caution
    Via StockStory
    News headline image
    What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call
    Via StockStory
    Topics Earnings Supply Chain
    News headline image
    Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
    Via StockStory
    Topics Earnings Economy
    News headline image
    Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges
    Via StockStory
    Topics Economy Supply Chain
    News headline image
    1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
    Via StockStory
    News headline image
    Supernus (SUPN) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates
    Via StockStory
    Topics Earnings
    News headline image
    Supernus Announces First Quarter 2026 Financial Results
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Supernus Pharmaceuticals Earnings: What To Look For From SUPN
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
    Via StockStory
    Topics Economy
    News headline image
    3 Unprofitable Stocks We Think Twice About
    Via StockStory
    News headline image
    1 Cash-Producing Stock to Consider Right Now and 2 Facing Headwinds
    Via StockStory
    News headline image
    Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    3 Reasons SUPN is Risky and 1 Stock to Buy Instead
    Via StockStory
    Topics Stocks Supply Chain
    News headline image
    Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales
    Via StockStory

    Frequently Asked Questions

    Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
    Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
    What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
    The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 45.35
    When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 06/11/26 01:17 PM ET
    What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.41B
    How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
    Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.